Compare Abbott Laboratories (ABT) vs Coupang Inc (CPNG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Coupang Inc — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while Coupang Inc trades at $18.98 (market cap $33.26B). The key difference: Abbott Laboratories is far larger — about 5× Coupang Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Coupang Inc pays none. Which is the better fit depends on your goals.
| ABT | CPNG | |
|---|---|---|
Market Cap | $166.94B | $33.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $33.53 |
52-Week Low | $82.57 | $15.12 |
Enterprise Value | $193.69B | $32.36B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Coupang (CPNG) trades at $18.53, showing minimal daily movement (-0.16%) amid mixed technical signals. The stock maintains bullish moving averages but faces resistance near $20. Fundamentally, revenue growth remains strong at $34.53B (2025) though profitability is inconsistent with recent quarterly EPS misses. Regulatory challenges emerged with a $409 million data breach fine in June 2026, though investor sentiment improved as the penalty was below worst-case fears.
Wall Street maintains strong bullish consensus (87.5% buy ratings) with a $25.80 price target implying 39% upside. Key opportunities include sustained e-commerce growth and operational cash flow strength ($1.77B in 2025), while risks center on regulatory scrutiny, competitive pressures, and volatile profitability. The stock's high P/E (184.18) requires continued execution to justify valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Coupang Inc
Coupang Inc is an e-commerce company. The company sells apparel, electronics, footwear, food products, furniture, nutritional supplements, and other products. Its segments include Product Commerce and Growth Initiatives.
Read more on CPNG →
